A post-authorisation, non-interventional, retrospective, drug-utilisation study to describe the pattern of use of lenalidomide in patients with myelodysplastic syndromes (MDS) (CC-5013-MDS-012)

First published 12/03/2018

Last updated 05/02/2025

EU PAS number:

EUPAS22604

Study

Finalised

Documents

Study protocol

Updated protocol

Protocol Amendment 3 (Version 2.0) 12 Apr 2023_Redacted.pdf

First published: 16/04/2024

English (866.2 KB - PDF) View document

Study results

Study report

CC-5013-MDS-012_FSR Abstract_Redacted.pdf

English (2.68 MB - PDF) View document

Other information

Secondary tabs